To End Tuberculosis, India must Embrace Innovation: Lessons from the ZeNix Trial Results
D. Behera
Citation Information :
Behera D. To End Tuberculosis, India must Embrace Innovation: Lessons from the ZeNix Trial Results. Indian J Chest Dis Allied Sci 2022; 64 (2):63-64.
World Health Organisation (WHO), 2020. Global Tuberculosis Report 2020. Available from: https://www.who.int/publications/i/item/9789240013131 (Accessed January 14, 2022).
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020;382(10):893–902. DOI: 10.1056/NEJMoa1901814.
Conradie F. High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid. IAS 2021, Berlin, Germany [Conference presentation].
Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrugresistant tuberculosis: a multicenter, randomized controlled trial (the NExT Study). Am J Respir Crit Care Med 2022;205:1214–1227.
Nyang'wa BT. TB-PRACTECAL trial results and next steps. Presented at the 52nd World Conference on Lung Health; 2021.
Lange C, Barry III, CE, et al. Treatments of multidrug-resistant tuberculosis: Light at the end of the tunnel. Am J Respir Crit Care Med 2022;205:1142-1143.
Mallick JS, Nair P, Abbew ET, et al. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. Jac-antimicrobial Resistance. 2022 Apr;4(2):dlac029. DOI: 10.1093/jacamr/dlac029. PMID: 35356403; PMCID: PMC8963286.
